Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAS-102 + Irinotecan in Advanced Gastric/GEJ Cancer
NCT04074343Phase 1Completed
- Sponsor
- University of California, Irvine
- Start
- Aug 2019
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of trifluridine + tipiracil in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by University of California, Irvine. Primary endpoint: Percentage of Participants With Progression-free Survival at 6 Months. Started Aug 2019; status: completed.
02
Drugs
trifluridine + tipiracil
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT04074343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04074343.